Sign in to view content

Complications, Compliance, and 2-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for PDR-Related Vitreous Hemorrhage

Dennis M. Marcus, MD

Video
Published 2020

Related

Impact of Delayed Treatment in Diabetic Retinal Disease: Experience From VISTA/VIVID and PANORAMA
Sunil Srivastava, MD
Annual Meeting Talks
2021
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020
Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more